BioScience Trends. 2011;5(2):52-56. (DOI: 10.5582/bst.2011.v5.2.52)

Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.

Inagaki Y, Qi FH, Gao JJ, Qu XJ, Hasegawa K, Sugawara Y, Tang W, Kokudo N


c-Met, a type of receptor tyrosine kinase, may be significantly associated with the progression of hepatocellular carcinoma (HCC). In addition, des-γ-carboxyprothrombin (DCP) has been found to interact with c-Met and activate HCC cell growth. Therefore, the functional inhibition of c-Met expressed on HCC cells should arrest HCC cell growth. The present study found that the c-Met inhibitor SU11274 suppressed HCC cell growth by inhibiting the activation of c-Met. Furthermore, this inhibitor also neutralized the activation of HCC cell growth resulting from the addition of DCP. These results suggest that the functional inhibition of c-Met might be a target for the development of chemotherapeutic agents for HCC, and especially those that are positive for expression of DCP.

KEYWORDS: c-Met, hepatocellular carcinoma (HCC), inhibitor, growth, des-γ-carboxyprothrombin (DCP)

Full Text: